A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: COVID-19 Infection

In brief

This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized for observation or study intervention administration but do not require supplemental oxygen for COVID-19.

Key facts

Study ID: NCT07013474
Run by: Pfizer
People needed: 300
Starts: 2025-07-14
Expected to finish: 2028-02-25
Last updated by the study team: 2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

18 years of age or older at screening who are non-hospitalized or hospitalized for observation or with the intent of administering the study intervention.
Confirmed SARS-CoV-2 infection as determined by RAT (or other locally approved test) collected within 2 days prior to randomization. Initial onset of symptoms attributable to COVID-19 within 5 days prior to the day of randomization and at least 1 of the specified symptoms attributable to COVID-19 present on the day of randomization.
Severely immunocompromised due to:
Solid organ or islet cell transplant recipient who is receiving immunosuppressive therapy;
Active hematologic malignancy (eg, chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia);
Receipt of CAR-T-cell therapy or HCT either within 2 years of transplantation or who are receiving immunosuppressive therapy;
Currently receiving or recently received B-cell depleting therapies (eg, rituximab), where the immunosuppressive effect is still ongoing.

You may not qualify if…

Severe COVID-19, or current need for supplemental oxygen for treatment of COVID-19.
Receiving dialysis or have current kidney failure (ie, eGFR consistently <15 mL/min/1.73 m2)
Active liver disease
History of hypersensitivity or other contraindication to any of the components of the study interventions, as determined by the investigator
Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.
Life expectancy less than 30 days at study entry due to an underlying condition, in the judgement of the investigator.
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Has received any other antiviral for the treatment of the current COVID-19 infection
Current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s).
Current or previous administration of an investigational product (drug or vaccine) within 30 days (or as determined by local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). Authorized or products with conditional approval are not considered investigational.
Prior participation in this trial or any clinical trial of ibuzatrelvir.
Females who are pregnant, breastfeeding, or who are planning to become pregnant within the timeframe of the study.
Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Where it is running

Amicis Research Center - Granada Hills — Granada Hills, California, United States (enrolling)
Jacobs Medical Center at UC San Diego Health — La Jolla, California, United States (enrolling)
UC Davis CTSC Clinical Research Center — Sacramento, California, United States (enrolling)
University of California Davis Health — Sacramento, California, United States (enrolling)
UC San Diego Medical Center - Hillcrest — San Diego, California, United States (enrolling)
University of California San Diego Health — San Diego, California, United States (enrolling)
UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus — Aurora, Colorado, United States (enrolling)
University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States (enrolling)
University of Colorado Clinical and Translational Research Center — Aurora, Colorado, United States (enrolling)
University of Colorado Hospital — Aurora, Colorado, United States (enrolling)
Georgetown University Medical Center — Washington D.C., District of Columbia, United States (enrolling)
BRP- Hialeah Hospital — Hialeah, Florida, United States (enrolling)
D&H Cancer Research Center LLC — Margate, Florida, United States (enrolling)
Kendall South Medical Center — Miami, Florida, United States (enrolling)
Velocity Clinical Research, Savannah — Savannah, Georgia, United States (enrolling)
Humphreys Diabetes Center — Boise, Idaho, United States (enrolling)
St. Luke's Idaho Elks Children's Pavilion — Boise, Idaho, United States (enrolling)
Northwestern Memorial Hospital — Chicago, Illinois, United States (enrolling)
Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States (enrolling)
Johns Hopkins Hospital — Baltimore, Maryland, United States (enrolling)
Jadestone Clinical Research — Silver Spring, Maryland, United States (enrolling)
Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)
Clinical Trials Center — Boston, Massachusetts, United States (enrolling)
Clinical Trials Hub — Boston, Massachusetts, United States (enrolling)
Hope Clinical Research, Inc. — Canoga Park, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.